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Introduction
Choroid plexus tumors (CPT) are primary intraventricular 
neoplasms of the central nervous system (CNS), arising from 
the choroid plexus epithelium, with an incidence of 0.4–
0.9% in human beings and 10% in dogs.28,36 The majority of 
human CPTs occur in childhood, whereas in dogs, middle-
aged animals are typically affected.28,36 In adult people and 
dogs, CPTs occur most commonly in the fourth ventricle; 
however, in children, CPTs are usually found in the lateral 
ventricles.21,36 According to the current 2007 human World 
Health Organization (WHO) classification scheme, human 
CPTs are classified into 3 different grades: choroid plexus 
papillomas (CPP, grade I), atypical choroid plexus papillo-
mas (atypical CPP, grade II), and choroid plexus carcinomas 
(CPC, grade III).21 Increasing tumor grade correlates 
inversely with survival time after surgery and is therefore an 
important prognostic factor.28 In dogs, although several his-
tological grading schemes for canine CPTs have been pro-
posed, their clinical impact and usefulness is unknown due to 
lack of prospective studies.7,27,36 Because of the histologic 
similarities between canine and human CPTs, the most 
recently proposed canine classification scheme is based on 
the same criteria as the current human WHO classification.36 
Information on molecular events involved in tumor transfor-
mation and progression of CPTs are only partially known.18,34
The key role of E-cadherin in progression of epithelial 
tumors is well established.19,20,30 E-cadherin belongs to the 
cadherin family, which are calcium-dependent transmem-
brane glycoproteins involved in cell-to-cell adhesion by 
homophilic interaction between their extracellular domains 
of 2 adjacent cells. E-cadherin, whose intracellular domain is 
connected to the actin cytoskeleton via catenins such as 
β-catenin, is typically expressed by epithelial cells. 
E-cadherin dysfunction is associated with loss of E-cadherin 
expression or its relocation from the membranes to the cyto-
plasm and nuclear compartment, which results in a process 
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Abstract. Expression of E-cadherin and β-catenin has been widely studied in various human and canine epithelial tumors and 
has been correlated with dedifferentiation, invasiveness, and metastasis. Choroid plexus tumors (CPTs) are of epithelial origin, 
and the most important prognostic factor in human medicine is the tumor grade. Limited information is available regarding 
E-cadherin and β-catenin expression in human CPTs, and no information is found in the veterinary literature. In the current 
study, 42 canine CPTs (19 choroid plexus papillomas and 23 choroid plexus carcinomas) were retrospectively reviewed, and 
the intensity and cellular staining pattern of E-cadherin and β-catenin were correlated with histological features, paying special 
attention to grade, invasion, and metastasis. In addition, cytokeratin and glial fibrillary acidic protein (GFAP) antibodies were 
evaluated as markers for canine CPTs. It was found that loss of E-cadherin and β-catenin expression was uncommon in canine 
CPTs. Rather, membranous expression of both molecules was increased in CPTs compared to normal choroid plexus (NCP), 
regardless of tumor grade. Additionally, aberrant cytoplasmic or nuclear expression of both E-cadherin and β-catenin was 
often observed in CPTs. GFAP was frequently expressed in CPTs in contrast to NCP. None of these parameters were correlated 
with malignancy, and therefore, do not appear to be useful for prognostic information. Nevertheless, a panel of antibodies 
including E-cadherin and GFAP might be useful to support the diagnosis of CPTs and help to differentiate them from other 
tumors, such as ependymomas and metastatic epithelial tumors.
Key words: β-catenin; canine; choroid plexus tumor; cytokeratin; E-cadherin; glial fibrillary acidic protein.
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called epithelial-to-mesenchymal transition, during which 
epithelial cells lose their intercellular adhesion and polarity 
hence adopting a mesenchymal cell shape. Epithelial-to-
mesenchymal transition facilitates tumor invasiveness and 
metastasis.16,19,20,26 In human medicine, loss of E-cadherin 
expression has been correlated with dedifferentiation, inva-
siveness, and metastasis.19,20,30 In veterinary medicine, the 
few studies that have investigated E-cadherin expression 
have evaluated canine epithelial tumors and meningiomas. 
There are indications that in canine epithelial tumors, loss 
and relocation of E-cadherin expression is associated with 
malignancy.*
The aim of the current study was to gain insight into the 
role of E-cadherin and β-catenin in tumor progression, local 
brain invasion, and metastasis of canine CPTs. The relation-
ship between E-cadherin and tumor malignancy in CPTs is not 
clear as data about E-cadherin and β-catenin expression in 
canine CPTs are lacking, and only a single study has investi-
gated E-cadherin expression in a small number of human 
CPPs.31 To this end, intensity and cellular staining pattern of 
immunohistochemical E-cadherin and β-catenin expression 
was investigated in a large series of canine CPPs and CPCs 
and compared to normal choroid plexus (NCP) tissue. In addi-
tion, the immunohistochemical performance of the E-cadherin 
and β-catenin antibodies as markers for canine CPTs was 
compared to that of cytokeratin and glial fibrillary acidic pro-
tein (GFAP) antibodies. It was hypothesized that E-cadherin 
and β-catenin expression would decrease and that subcellular 
localization of both molecules would change with increasing 
tumor grade, local brain invasion, and metastasis.
Materials and methods
Animals and tumor tissue
Tissues from 42 canine CPTs from the neuropathology archives 
of both the NeuroCenter, Department of Clinical Research and 
Veterinary Public Health, University of Bern (Switzerland; 13 
cases) and the Department of Pathology, Microbiology and 
Immunology, School of Veterinary Medicine, University of 
California–Davis (California; 29 cases)36 were included in the 
present retrospective study. Inclusion criteria were the histologi-
cal diagnosis of a CPP or CPC in the brain and/or spinal cord. In 
35 cases, tumor tissue was collected during necropsy, while in 7 
cases tissue was obtained from surgical biopsy. In addition, tis-
sues from choroid plexuses of 10 neurologically normal dogs 
(NCP) were included as normal control tissue.
Histopathology and grading
All tumors were formalin-fixed (10%) and paraffin-embedded. 
Sections were cut at 5 µm and stained with hematoxylin and 
eosin. Histological grading was performed independently by 
2 neuropathologists (AO, RJH) according to a recent study 
of canine CPTs, which is based on the current diagnostic cri-
teria of the 2007 human WHO classification of human CNS 
tumors.1,36 Criteria for grading are listed in Table 1. Tumors 
with evidence of metastasis were directly classified as carci-
noma regardless of their histological features. In addition, 
the following criteria were assessed: location of the tumor, 
presence of local brain invasion, evidence of peripheral cap-
illary proliferation, infiltrates with mononuclear inflamma-
tory cells, and mineralization.
Immunohistochemistry
All CPTs and NCPs were investigated with immunohisto-
chemistry using antibodies to GFAP (rabbit polyclonal),a 
cytokeratin CAM5.2 (cytokeratin 7, 8; mouse monoclonal),b 
cytokeratin wide spectrum (cytokeratin 4, 5, 6, 8, 14, 16; rab-
bit polyclonal),a E-cadherin (mouse monoclonal, clone 36),b 
and β-catenin (mouse monoclonal, clone 14),b respectively. 
Sections were deparaffinized in xylene and rehydrated in 
100% ethanol. Endogenous peroxidase activity was quenched 
with 3% hydrogen peroxide in methanol. Antigen was then 
demasked by heat retrieval in citrate buffer (pH 6.0)a at 99°C 
for 20 min using a laboratory microwave (E-cadherin, 
β-catenin) or by proteolytic treatment with protease (GFAP), 
0.25% trypsin at 37°C (CAM5.2), or a combination of 0.5% 
trypsin and chymotrypsin at 37°C (wide spectrum cytokera-
tin). Tissue sections were then blocked with 5% normal goat 
serum for 30 min. The sections were then incubated with the 
primary antibodies either overnight at 4°C (E-cadherin, 
1:100; β-catenin, 1:100; CAM5.2, undiluted; and cytokeratin 
wide spectrum, 1:500) or for 1 hr at room temperature 
(GFAP, 1:500). Subsequent steps were performed with a 
commercial kita according to the manufacturer’s instruc-
tions. Sections of normal skin (E-cadherin, β-catenin, 
CAM5.2, wide spectrum cytokeratin) and brain (GFAP) 
were used as positive controls. For negative controls, the pri-
mary antibody was replaced by unspecific immunoglobulin 
G from nonimmunized mice or rabbits, as appropriate.
The percentage of positive immunoreactive cells in tumors 
and NCP (% total staining) was estimated. Additionally, the 
intensity of the staining was assessed semiquantitatively (0–
3), and the staining pattern (membranous, cytoplasmic, 
nuclear) was determined. On the basis of the percentage of 
positive cells, each tumor was defined within 1 of 4 groups as 
follows: negative, <30%, 30–60%, or >60% positive.
Statistical analysis
The statistical analysis was performed with statistical 
software.c Data were not normally distributed. Continuous 
data were compared with the Mann–Whitney rank-sum test 
and categorical data with the Fisher exact test. P ≤ 0.05 was 
considered significant.*References 3, 4, 10, 11, 15, 22–26, 29
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Results
Animals
Information regarding breed and age was available in 38 
cases. The majority (25/38) were large-breed dogs with the 
Labrador Retriever and Golden Retriever being most com-
mon. Median age was 5 years (range: 3–14 years) in dogs 
with CPP and 7 years (range: 3–12 years) in dogs with CPC 
(not significantly different). Information on sex was only 
available in 34 dogs, with 15 females (1 intact) and 19 males 
(5 intact). There were no significant sex differences between 
CPP and CPC.
Histopathology and grading
Nineteen (45%) of the 42 tumors were classified as CPP and 
23 (55%) as CPC (Table 2). No atypical CPT was identified. 
Tumor localization was similar for CPP and CPC, with 24 
tumors (57%) located in the fourth ventricle and 7 tumors 
(17%) each in the third and in the lateral ventricles. Eight 
CPC had metastases within the CNS. In 4 additional cases, 
the primary mass was not identified but several masses were 
observed within the ventricular system or in the spinal 
meninges. Results of the histological characterization are 
summarized in Figure 1 and Table 1.
Immunohistochemistry
E-cadherin and β-catenin expression. Results are sum-
marized in Figures 2 and 3. E-cadherin and β-catenin expres-
sion was observed in all NCP as well as in all CPTs, regardless 
of histological grade (Fig. 4). Multifocal areas with weak or 
absent E-cadherin and β-catenin expression were frequently 
present in both NCP and CPTs (Fig. 2). In the majority of 
CPTs, E-cadherin and β-catenin expression was more intense 
than in NCP, regardless of tumor grade. A few CPPs and CPCs 
showed very weak expression diffusely throughout the tumor, 
but it was not a consistent feature of CPTs. Importantly, no 
significant loss of E-cadherin and β-catenin expression was 
observed with increasing malignancy.
In NCP, E-cadherin and β-catenin were expressed strictly 
at the basolateral cell membranes. Neither cytoplasmic nor 
nuclear expression was observed. In contrast, CPTs frequently 
Table 1. Classification of canine choroid plexus tumors.*
Histological grade Histological features
Choroid plexus papilloma (grade I) Histological features of normal choroid plexus with minimal histological change, 
with or without minimal brain invasion; <2 mitotic figures per 10 high power fields 
(HPF)
Atypical choroid plexus papilloma (grade II) ≥2 mitoses per 10 HPF; up to 2 of the following: increased cellularity, nuclear atypia, 
loss of papillary pattern, and areas of necrosis
Choroid plexus carcinoma (grade III) At least 4 of the following: ≥5 mitotic figures per 10 HPF, nuclear atypia, multi-
layering of epithelium, increased cellularity, loss of papillary pattern with solid cell 
sheets, and multifocal areas of necrosis
*According to Westworth et al.36
Table 2. Summary of the anatomical localization in 42 choroid 
plexus tumors: choroid plexus papilloma (CPP) and choroid 
plexus carcinoma (CPC).*
No. of cases
 CPP CPC
3rd ventricle 3 (16) 4 (17)
4th ventricle 10 (53) 14 (61)
Lateral ventricle 6 (32) 1 (4)
Spinal meninges 0 3 (13)
Entire ventricle system 0 1 (4)
Total 19 23
*Numbers in parentheses are percentages. Figure 1. Summary of histological features in 19 choroid 
plexus papilloma (CPP) and 23 choroid plexus carcinoma (CPC). 
Assessed features: <2, ≥2, or ≥5 mitotic figures (MF) per 10 
high-powered field; IC = increased cellularity; NA = nuclear 
atypia; PP = loss of papillary pattern; NE = areas of necrosis; 
MU = multi-layering of epithelium; ME = metastasis; BI = local 
brain invasion; CP = capillary proliferation in periphery; MI = 
mononuclear infiltrates; MN = mineralization; asterisk (*) = 
criteria used for grading.
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showed cytoplasmic and/or nuclear expression of both 
E-cadherin and β-catenin regardless of histological grade of 
the tumor (Fig. 5). However, both staining patterns occurred 
only in a fraction of tumor cells and were consistently asso-
ciated with loss of membranous expression in these cells. In 
all tumors, membranous expression was preserved in tumor 
areas without aberrant subcellular localization of E-cadherin 
and β-catenin (Fig. 3). Notably, metastases of CPCs exhib-
ited large areas of strong membranous immunoreactivity. In 
contrast to the definite membranous expression in NCP, the 
membranous staining in CPTs appeared blurred (Fig. 4). No 
significant increase of cytoplasmic or nuclear expression 
was observed in CPCs versus CPPs (Fig. 3). Interestingly, in 
all cases with nuclear E-cadherin expression (6 cases, P = 
0.005) and in 80% of tumors with nuclear β-catenin expres-
sion (7 cases, P = 0.01), local invasion of the tumor into adja-
cent brain tissue was apparent, independent of tumor grade. 
But in the majority of these tumors, nuclear expression was 
topographically unrelated to tumor invasion.
GFAP expression. Normal choroid plexuses were con-
sistently negative for GFAP immunoreactivity (Fig. 4). In 
contrast, 55% of the tumors had a strong cytoplasmic GFAP 
immunoreactivity (Figs. 2, 4). In most tumors, GFAP expres-
sion occurred multifocally in groups of neoplastic cells and, 
in only a small number of tumors, the expression occurred in 
more than 50% of the tumor cells. The proportion of tumors 
expressing GFAP was similar for CPPs and CPCs (Fig. 2). 
Also, no significant difference in expression intensity was 
found between CPPs and CPCs.
Cytokeratin expression. Immunohistochemistry for 
CAM5.2 and wide spectrum cytokeratin gave very similar 
results. Only 3 out of 10 NCP and 4 out of 10 NCP were 
Figure 2. Summary of immunohistochemical results in neoplastic and non-neoplastic choroid plexus (A–E). On the basis of the 
percentage of positive cells, the tumors were grouped as follows: 0 = no expressing cells, <30% positive cells, 30–60% positive cells, >60% 
positive cells. NCP = normal choroid plexus; CPP = choroid plexus papilloma; CPC = choroid plexus carcinoma; GFAP = glial fibrillary 
acidic protein.
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immunoreactive with CAM5.2 and wide spectrum cytokera-
tin, respectively. The proportion of immunoreactive tumors 
was higher in CPTs compared to NCP with no statistically 
significant difference between CPP and CPC (Fig. 2). In both 
NCP and CPTs, the percentage of immunoreactive cells was 
low in most cases and focally restricted. Also, with both cyto-
keratin antibodies, staining was consistently cytoplasmic in 
normal and neoplastic choroid plexus epithelium (Fig. 4).
Discussion
Reduced or aberrant expression of E-cadherin and β-catenin 
has been described in various human and canine epithelial 
tumors and has been correlated with dedifferentiation, inva-
siveness, and metastasis.4,9,10,16,20,30 Therefore, their associa-
tion to histological grading and their role in invasion and 
metastasis of canine CPTs was investigated in the current 
study.
E-cadherin and β-catenin expression was found in all 
CPTs. Results are comparable with a human study that 
observed E-cadherin expression in all of 5 CPPs examined.31 
The expression of both molecules appeared to be stronger in 
most CPTs and metastases compared to NCP. Results of the 
current study coincide only partially with former studies that 
found an increased E-cadherin expression in differentiated 
tumors, but reduced expression in undifferentiated tumors 
and metastases.13,31 Rather, results support another study that 
hypothesized that at a later stage strong membranous 
E-cadherin expression might facilitate the stabilization of 
tumor metastases in a new environment in order to re-establish 
tissue architecture.4 Nevertheless, single benign and malig-
nant CPTs showed significant decrease or loss of E-cadherin 
and β-catenin expression, suggesting that although down-
regulation is not consistently involved in CPT tumorigene-
sis, it might occur sporadically in CPTs.
Abnormal expression patterns such as cytoplasmic or 
nuclear dislocation in CPTs were also observed in the current 
study when compared to NCP. These results are in line with 
studies of other epithelial tumors using antibodies against the 
cytoplasmic domain of E-cadherin.8,14,29 While nuclear 
expression of β-catenin is generally well recognized in sev-
eral tumor types, it has not yet been detected in CPTs. 
Nuclear expression of E-cadherin has only been discovered 
recently in several human tumor types6,9,12 and in canine anal 
sac gland carcinoma.22 It is thought that decreased or aber-
rant expression may remove the regulatory effect of contact 
inhibition on proliferation, thus allowing an escape from 
growth control signals resulting in unrestricted replication of 
tumor cells.4 Interestingly, in the present study, a switch from 
membranous to cytoplasmic and nuclear expression occurred 
generally only in a subfraction of neoplastic cells, whereas 
other areas of the same tumor had clear membranous stain-
ing. It is unknown whether this localized aberrant expression 
pattern of E-cadherin and β-catenin has been observed in 
other tumor types. Results of the present study suggest that 
escape from inhibitory signals does not occur simultane-
ously in all tumor cells. Rather, some tumor areas might be 
proliferously active whereas others are not. This possibility 
might be confirmed by further studies using proliferation 
markers. Although a statistical correlation between nuclear 
expression and brain invasion was observed, it seems to be 
unlikely that brain invasion is causally related to nuclear 
expression because it occurred in the majority of cases in 
areas without nuclear relocalization. Additionally, all metas-
tases strongly expressed E-cadherin and β-catenin at their 
cellular membranes not supporting a causative role of aber-
rant E-cadherin or β-catenin expression in metastasis of 
CPTs. Apparently mechanisms other than loss of E-cadherin 
endow CPTs with invasive and metastatic properties.
Taken together, because both antibodies detected all NCPs 
and all CPTs, the antibodies may be useful markers for CPTs. 
Notably, E-cadherin might help to differentiate CPTs from 
ependymomas, as ependyma does not express E-cadherin.13,31 
Nevertheless, in contrast to other epithelial tumors,15,29 neither 
downregulation nor aberrant expression is associated with 
malignancy and therefore, assessment of E-cadherin and 
β-catenin expression appears not to be useful for grading of 
canine CPTs. However, because there is no confirmation that 
Figure 3. Subcellular localization of E-cadherin (A) and β-
catenin (B) in normal and neoplastic choroid plexuses as determined 
by immunohistochemistry. Percentages refer to the ratio of NCPs 
and CPTs expressing the molecules at a specific localization. 
Aberrant (cytoplasmic and nuclear) expression occurred always in 
addition to membranous expression in other areas of a given tumor. 
NCP = normal choroid plexus; CPP = choroid plexus papilloma; 
CPC = choroid plexus carcinoma.
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Figure 4. Representative examples of expression of E-cadherin (a), β-catenin (b), GFAP (c), wide spectrum cytokeratin (d), and CAM 5.2 
(e) in normal choroid plexus (NCP), choroid plexus papilloma (CPP), and choroid plexus carcinoma (CPC), 400×. a, E-cadherin is expressed 
membranously in NCP. In most CPPs and CPCs, E-cadherin expression is increased, but the membranous pattern is not definite as in NCP. b, β-
catenin is expressed membranously in NCP. As with E-cadherin, expression is increased in most CPPs and CPCs, but the membranous pattern is 
not definite as in NCP. c, GFAP is not expressed in NCP. Note the strong GFAP expression in the white matter of the brainstem (asterisk) and in the 
overlaying ependyma (arrow). In a CPP and in a CPC metastasis of the spinal cord (arrowhead: spinal nerve root), GFAP expression is apparent. 
d, wide spectrum cytokeratin is only focally expressed in NCP. Some CPPs and CPCs show strong and focal cytokeratin expression. e, CAM 5.2 
shows a similar focal expression pattern as wide spectrum keratin (same NCP, CPP, and CPC as in panel d), but the expression is weaker.
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the grading system used in the current study reflects the prog-
nostic accuracy of that demonstrated in human tumors, prog-
nostic studies are required to confirm the usefulness of this 
grading system in dogs. Lack of correlation between aberrant 
E-cadherin and β-catenin expression and tumor grade has also 
been observed in meningiomas.5,33
Figure 5. Aberrant expression of E-cadherin and β-catenin in CPTs without brain invasion (a–d) and CPTs with brain invasion (e, 
f ). a, membranous and cytoplasmic (arrow) expression of E-cadherin in a CPP extending into the cerebellar meninges, 400×. b, nuclear 
expression of E-cadherin in a CPP, 400×. c, strong cytoplasmic expression und multifocal nuclear expression (arrow) of β-catenin in a CPP, 
400×. d, nuclear β-catenin expression (arrows) in a CPP, 400×. e, cytoplasmic E-cadherin expression in invasive neoplastic cells. Some cells 
adapt a spindloid morphology (arrow), 400×. f, cytoplasmic β-catenin expression in neoplastic cells that invade the brain parenchyma, 400×.
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GFAP staining was consistently negative in NCP epithe-
lium, which confirms previous studies in human beings and 
dogs.7,28 However, a large proportion of CPPs and CPCs 
strongly expressed GFAP in contrast to previous studies on 
canine CPTs, in which most tumors did not express 
GFAP.7,27,35 In comparison, GFAP immunoreactivity has 
been reported in 25–58% of human CPTs.2,28,32 The presence 
of GFAP in CPTs has been interpreted as evidence of local 
ependymal differentiation of neoplastic cells.28 If true, then 
findings from the present study suggest that, in dogs, epen-
dymal differentiation occurs in a large proportion of both 
CPPs and CPCs, but its appearance is not correlated with 
histological grade as has been suggested for human CPTs.17,32
Wide spectrum cytokeratin and CAM5.2 were expressed 
by an unexpectedly low number of both NCP and CPTs indi-
cating that neither is an optimal marker of CPTs. Results of 
the current study are in contrast to most other studies, in 
which cytokeratin is expressed by both normal and neoplas-
tic choroid plexus epithelium.2,7,28,32 This major discrepancy 
from previous human and canine studies cannot be explained. 
However, comparison of results from different studies is dif-
ficult because of various cytokeratin antibodies used in the 
literature, small sample numbers, and different grading 
systems.
In conclusion, consistent decrease or loss of E-cadherin or 
β-catenin expression in canine CPTs was not found, but aber-
rant subcellular expression was observed in a large propor-
tion of CPTs. In focal areas of these CPTs, a switch from 
membranous to cytoplasmic and/or nuclear expression could 
be detected. GFAP was expressed in a large number of CPTs, 
but not in NCP epithelium. However, none of these parame-
ters were correlated with malignancy, and therefore, none of 
these markers are useful for prognostic information. 
Nevertheless, a panel of antibodies including E-cadherin and 
GFAP might be useful to differentiate CPTs from other 
tumors such as ependymomas and metastatic epithelial 
tumors.
Acknowledgements
The authors thank Drs. Mark Vandevelde and Amy Grooters for 
critical reading of the manuscript.
Sources and manufacturers
a. EnVision, Dako Schweiz AG, Baar, Switzerland.
b. BD Biosciences, Allschwil, Switzerland.
c. NCSS software, NCSS, Kaysville, UT.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with 
respect to the research, authorship, and/or publication of this 
article.
Funding
The author(s) received no financial support for the research, 
authorship, and/or publication of this article.
References
 1. Aguzzi A, Brandner S, Paulus W: 2007, Choroid plexus tumors. 
In: World Health Organization classification of tumours: 
pathology and genetics of tumours of the nervous system, ed. 
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, pp. 84–86. 
IARC Press, Lyon, France.
 2. Beschorner R, Pantazis G, Jeibmann A, et al.: 2009, Expres-
sion of EAAT-1 distinguishes choroid plexus tumors from nor-
mal and reactive choroid plexus epithelium. Acta Neuropathol 
117:667–675.
 3. Brunetti B, Sarli G, Preziosi R, et al.: 2005, E-cadherin and 
beta-catenin reduction influence invasion but not proliferation 
and survival in canine malignant mammary tumors. Vet Pathol 
42:781–787.
 4. Brunetti B, Sarli G, Preziosi R, et al.: 2003, E-cadherin expres-
sion in canine mammary carcinomas with regional lymph node 
metastases. J Vet Med A Physiol Pathol Clin Med 50:496–500.
 5. Brunner EC, Romeike BFM, Jung M, et al.: 2006, Altered 
expression of beta-catenin/E-cadherin in meningiomas. Histo-
pathology 49:178–187.
 6. Burford H, Baloch Z, Liu X, et al.: 2009, E-cadherin/β-catenin and 
CD10: a limited immunohistochemical panel to distinguish pan-
creatic endocrine neoplasm from solid pseudopapillary neoplasm 
of the pancreas on endoscopic ultrasound-guided fine-needle aspi-
rates of the pancreas. Am J Clin Pathol 132:831–839.
 7. Cantile C, Campani D, Menicagli M, Arispici M: 2002, Patho-
logical and immunohistochemical studies of choroid plexus 
carcinoma of the dog. J Comp Pathol 126:183–193.
 8. Chetty R, Serra S: 2008, Membrane loss and aberrant nuclear 
localization of E-cadherin are consistent features of solid pseu-
dopapillary tumour of the pancreas. An immunohistochemical 
study using two antibodies recognizing different domains of 
the E-cadherin molecule. Histopathology 52:325–330.
 9. Chetty R, Serra S: 2008, Nuclear E-cadherin immunoexpres-
sion: from biology to potential applications in diagnostic 
pathology. Adv Anat Pathol 15:234–240.
10. De Matos AJF, Lopes CCC, Carvalheira J, et al.: 2006, E-cad-
herin expression in canine malignant mammary tumours: rela-
tionship to other clinico-pathological variables. J Comp Pathol 
134:182–189.
11. De Matos AJF, Lopes CCC, Faustino AMR, et al.: 2007, E-cad-
herin, β-catenin, invasion and lymph node metastases in canine 
malignant mammary tumours. APMIS 115:327–334.
12. El-Bahrawy MA, Rowan A, Horncastle D, et al.: 2008, E-cad-
herin/catenin complex status in solid pseudopapillary tumor of 
the pancreas. Am J Surg Pathol 32:1–7.
13. Figarella-Branger D, Lepidi H, Poncet C, Gambarelli D: 1995, 
Differential expression of cell adhesion molecules (CAM), 
neural CAM and epithelial cadherin in ependymomas and cho-
roid plexus tumors. Acta Neuropathol 89:248–257.
14. Fougner SL, Lekva T, Borota OC, et al.: 2010, The expression 
of E-cadherin in somatotroph pituitary adenomas is related to 
tumor size, invasiveness, and somatostatin analog response. J 
Clin Endocrinol Metab 95:2334–2342.
 at Bibliothek Be 155 on April 29, 2014vdi.sagepub.comDownloaded from 
22 Nentwig et al.
15. Gama A, Paredes J, Gärtner F, et al.: 2008, Expression of 
E-cadherin, P-cadherin and [beta]-catenin in canine malignant 
mammary tumours in relation to clinicopathological param-
eters, proliferation and survival. Vet J 177:45–53.
16. Guarino M: 2007, Epithelial-mesenchymal transition and 
tumour invasion. Int J Biochem Cell Biol 39:2153–2160.
17. Gyure KA, Morrison AL: 2000, Cytokeratin 7 and 20 expres-
sion in choroid plexus tumors: utility in differentiating these 
neoplasms from metastatic carcinomas. Mod Pathol 13: 
638–643.
18. Hasselblatt M, Mertsch S, Koos B, et al.: 2009, TWIST-1 is 
overexpressed in neoplastic choroid plexus epithelial cells and 
promotes proliferation and invasion. Cancer Res 69:2219–2223.
19. Hirohashi S, Kanai Y: 2003, Cell adhesion system and human 
cancer morphogenesis. Cancer Sci 94:575–581.
20. Jeanes A, Gottardi CJ, Yap AS: 2008, Cadherins and cancer: 
how does cadherin dysfunction promote tumor progression? 
Oncogene 27:6920–6929.
21. Louis D, Ohgaki H, Wiestler O, et al.: 2007, The 2007 WHO 
classification of tumours of the central nervous system. Acta 
Neuropathol 114:97–109.
22. Polton GA, Brearley MJ, Green LM, Scase TJ: 2007, Expres-
sion of E-cadherin in canine anal sac gland carcinoma and its 
association with survival. Vet Comp Oncol 5:232–238.
23. Ramos-Vara J, Miller M, Gilbreath E, Patterson J: 2010, Immu-
nohistochemical detection of CD34, E-cadherin, claudin-1, 
glucose transporter 1, laminin, and protein gene product 9.5 in 
28 canine and 8 feline meningiomas. Vet Pathol 47:725–737.
24. Reis A, Carvalheira J, Schmitt F, Gartner F: 2003, Immuno-
histochemical study of the expression of E-cadherin in canine 
mammary tumours. Vet Rec 152:621–624.
25. Restucci B, Maiolino P, Martano M, et al.: 2007, Expression 
of β-catenin, E-cadherin and APC in canine mammary tumors. 
Anticancer Res 27:3083–3089.
26. Restucci B, Martano M, De Vico G, et al.: 2009, Expression 
of E-cadherin, β-catenin and APC protein in canine colorectal 
tumours. Anticancer Res 29:2919–2925.
27. Ribas J, Mena H, Braund K, et al.: 1989, A histologic and 
immunocytochemical study of choroid plexus tumors of the 
dog. Vet Pathol 26:55–64.
28. Rickert CH, Paulus W: 2001, Tumors of the choroid plexus. 
Microsc Res Tech 52:104–111.
29. Sarli G, Preziosi R, De Tolla L, et al.: 2004, E-cadherin immu-
noreactivity in canine mammary tumors. J Vet Diagn Invest 
16:542–547.
30. Schmalhofer O, Brabletz S, Brabletz T: 2009, E-cadherin, 
β-catenin, and ZEB1 in malignant progression of cancer. Can-
cer Metastasis Rev 28:151–166.
31. Schwechheimer K, Zhou L, Birchmeier W: 1998, E-cadherin 
in human brain tumours: loss of immunoreactivity in malignant 
meningiomas. Virchows Arch 432:163–167.
32. Tena-Suck M, Salinas-Lara C, Rembao-Bojórquez D, Cas-
tillejos M: 2010, Clinicopathologic and immunohistochemical 
study of choroid plexus tumors: single-institution experience in 
Mexican population. J Neurooncol 98:357–365.
33. Tohma Y, Yamashima T, Yamashita J: 1992, Immunohisto-
chemical localization of cell adhesion molecule epithelial cad-
herin in human arachnoid villi and meningiomas. Cancer Res 
52:1981–1987.
34. Tomm M, Koch A, Mertsch S, et al.: 2009, Role of Wnt inhibi-
tory factor-1 and Wnt/wingless signaling in choroid plexus 
tumors. Pediatr Blood Cancer 53:1152–1155.
35. Vandevelde M, Fankhauser R, Luginbuhl H: 1985, Immuno-
cytochemical studies in canine neuroectodermal brain tumors. 
Acta Neuropathol 66:111–116.
36. Westworth DR, Dickinson PJ, Vernau W, et al.: 2008, Cho-
roid plexus tumors in 56 dogs (1985–2007). J Vet Intern Med 
22:1157–1165.
 at Bibliothek Be 155 on April 29, 2014vdi.sagepub.comDownloaded from 
